OXY
OXYGEN MOLECULE
Created: | 1999-07-08 |
Last modified: | 2024-09-27 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 2 |
Chiral Atom Count | 0 |
Bond Count | 1 |
Aromatic Bond Count | 0 |
Chemical Component Summary | |
---|---|
Name | OXYGEN MOLECULE |
Systematic Name (OpenEye OEToolkits) | molecular oxygen |
Formula | O2 |
Molecular Weight | 31.999 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | CACTVS | 3.341 | O=O |
SMILES | OpenEye OEToolkits | 1.5.0 | O=O |
Canonical SMILES | CACTVS | 3.341 | O=O |
Canonical SMILES | OpenEye OEToolkits | 1.5.0 | O=O |
InChI | InChI | 1.03 | InChI=1S/O2/c1-2 |
InChIKey | InChI | 1.03 | MYMOFIZGZYHOMD-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank ID | DB09140 |
---|---|
Name | Oxygen |
Groups |
|
Description | Oxygen is an element displayed by the symbol O, and atomic number 8. It is an essential element for human survival. Decreased oxygen levels may be treated with medical oxygen therapy. Treatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing blood flow resistance in the diseased lung, leading to decreased cardiovascular workload in an attempt to oxygenate the lungs. Oxygen therapy is used to treat emphysema, pneumonia, some heart disorders (congestive heart failure), some disorders that cause increased pulmonary artery pressure, and any disease that impairs the body's ability to take up and use gaseous oxygen. Higher level of oxygen than ambient air (hyperoxia) can be introduced under normobaric or hyperbaric conditions. |
Synonyms |
|
Brand Names |
|
Indication | Oxygen therapy in clinical settings is used across diverse specialties, including various types of anoxia, hypoxia or dyspnea and any other disease states and conditions that reduce the efficiency of gas exchange and oxygen consumption such as respiratory illnesses, trauma, poisonings and drug overdoses. Oxygen therapy tries to achieve hyperoxia [L745] to reduce the extent of hypoxia-induced tissue damage and malfunction. |
Categories |
|
ATC-Code | V03AN01 |
CAS number | 7782-44-7 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Cytochrome c oxidase subunit 1 | MFADRWLFSTNHKDIGTLYLLFGAWAGVLGTALSLLIRAELGQPGNLLGN... | unknown | agonist,activator |
NADPH oxidase 1 | MGNWVVNHWFSVLFLVVWLGLNVFLFVDAFLKYEKADKYYYTRKILGSTL... | unknown | agonist,activator |
Hemoglobin subunit beta | MVHLTPEEKSAVTALWGKVNVDEVGGEALGRLLVVYPWTQRFFESFGDLS... | unknown | binder |
Hemoglobin subunit alpha | MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLS... | unknown | binder |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
PubChem | 977 |
ChEMBL | CHEMBL1234886 |
ChEBI | CHEBI:15379, CHEBI:26689, CHEBI:27140 |
CCDC/CSD | LOZNET, DEFHII, YUZLEN, ZIVSOP, YUJKIA, TUWWEO, ITEVUY07, ITEVUY01, ASAKUA, ITEVUY08, ITEVUY03, ITEVUY04, BEVFEP, ITEVUY05, BEVFUF, ITEVUY02 |
COD | 1512527 |